International Journal of Research in Pharmacy and Pharmaceutical Sciences

International Journal of Research in Pharmacy and Pharmaceutical Sciences


International Journal of Research in Pharmacy and Pharmaceutical Sciences
International Journal of Research in Pharmacy and Pharmaceutical Sciences
Vol. 4, Issue 1 (2019)

Steroid induced fractures and bone loss


Aleena Mathew, Cheryln Ann Chacko, Dr. Abel Abraham Thomas, Dr. Elssy Abraham

Bone loss is one of the most serious adverse effects experienced bythe patients receiving long term corticosteroid therapy. Bone loss occurs soon after corticosteroid therapy is initiated and results from a complex mechanism involving osteoblastic suppression and increased bone resorption. Long term administration of the steroidal drugs causes a 5 -15 % chance of bone loss. Oral and inhaled steroids and to an extent the topical steroidal preparations also induce severe bone loss. The risk of bone loss and fractures are directly dependent on the dose of the steroidal drugs. The steroidal therapy affects mainly the axial skeleton and femur. Prevention or treatment of the osteoporosis in patients on corticosteroid therapy should be considered as important as the steroid therapy. Risedronate, Bisphosphonates and Alendronate are the current gold standard for the prevention and treatment of Glucocorticoid induced bone loss. Other alternatives of treatment include calcitonin, cholecalciferol, fluorides, hormone replacement therapy and parathormone.
Download  |  Pages : 53-56
How to cite this article:
Aleena Mathew, Cheryln Ann Chacko, Dr. Abel Abraham Thomas, Dr. Elssy Abraham. Steroid induced fractures and bone loss. International Journal of Research in Pharmacy and Pharmaceutical Sciences, Volume 4, Issue 1, 2019, Pages 53-56
International Journal of Research in Pharmacy and Pharmaceutical Sciences